Read-Gene S.A. Stock Price

Read-Gene S.A. engages in the detection, prevention, and treatment of various types of cancer. Its activities include chemoprevention, clinical tests, and genetic tests. The chemoprevention segment engages in the use of natural or synthetic substances to inhibit, reverse, or delay the process of cancer. The company conducts clinical trials in cancer patients; and provides genetic tests and genetic oncology consultations to all patients for the most common cancers, such as breast, ovary, prostate, stomach, large intestine, and breast cancer. It also operates an online platform. The company was incorporated in 2005 and is based in Dobra, Poland. Read-Gene S.A. is a subsidiary of Gen-Pat-Med Sp. z o.o.